

GENOMIC VALLEY BIOTECH LTD.

Regd. Off: 4 K.M. Stone, Berri Chhara Road, Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507

CIN: L01122HR1996PLC033029

Tele :- +91-9811341542

Email : genomicvalley@gmail.com

Visit : <http://www.genomicvalley.com>

Dated: 29th May, 2017

To,

BSE Limited

PhirozeJeejeebhoy Towers,

Dalal Street, Fort

Mumbai-400001

Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Outcome of the Board Meeting held on 29th May, 2017

Dear Sir/Madam,

Pursuant to the Regulation 30 and any other applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors at its meeting held on 29th May, 2017, has inter-alia, approved the Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2017.

Further pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2017.

We are also enclosing a copy of the Auditor's Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further we are enclosing a copy of Declaration given by Managing Director and Chief Financial Officer pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and Circular no. CIR/ CFD/ CMD/56/2016 dated May, 27, 2016.

The aforesaid Board Meeting commenced at 11:45 AM and concluded at 03:00 P.M.

This is for your information and records.

Please acknowledge the receipt.

Thanking you.

Yours faithfully,

**For and on behalf of
Genomic Valley Biotech Limited**

Hitesh

Hitesh Kumar

Company Secretary & Compliance officer



Encl: A/A

GENOMIC VALLEY BIOTECH LIMITED
Reqd. Off: 4 KM STONE, BERRI CHHARA ROAD, VILLAGE-KHERKA MUSALMAN, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1996PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter and year ended
31 March 2017

Highlights of the Audited financial results as compared to the previous year are:

(Amount in ₹)

Sr. No.	Particular	Quarter Ended			Year Ended	
		31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16
		Audited	Unaudited	Audited	Audited	Audited
Part I						
1	Income From Operations					
	a) Net Sales/Income From Operations (Net of excise duty)	1,236,320	786,000	265,665	4,412,664	1,090,205
	b) Other Operating Income	-	-	-	-	-
	Tota income from operation (net)	1,236,320	786,000	265,665	4,412,664	1,090,205
2	Expenses					
(a)	Cost of materials consumed	27,600	266,381	66,304	976,572	729,289
(b)	Purchases of Stock-in-Trade	-	-	-	-	-
(c)	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-
(d)	Employee benefits expense	798,807	685,801	233,204	2,469,226	1,337,816
(e)	Depreciation and amortization expense	65,241	122,318	129,314	428,988	501,955
(f)	Other expenses (Any item exceeding 10% of the total expenses relating to continuing operation to be shown separately)	246,842	238,735	306,237	1,998,977	3,619,175
	Total Expenses	1,138,490	1,313,235	735,059	5,873,763	6,188,234
3	Profit / (Loss) from operations before other income, finance costs and exceptional item	97,830	-527,235	-469,394	-1,461,099	-5,098,029
4	Other Income	150,750	154,750	-1,240,680	762,639	1,649,604
5	Profit/loss from ordinary activity before financial cost & exceptional items(3±4)	248,580	-372,485	-1,710,074	-698,461	-3,448,426
6	Financial cost	-	-	-	-	-
7	Profit from ordinary activity after financial cost but before exception item	248,580	-372,485	-1,710,074	-698,461	-3,448,426
8	Exceptional Item	-	-	-	-	-
9	Profit From ordinary activities before tax	248,580	-372,485	-1,710,074	-698,461	-3,448,426
10	Tax expenses	-12,729	-	-100,600	-12,729	-100,600
11	Net Profit/(Loss) from ordinary activities after tax	261,309	-372,485	-1,609,474	-685,732	-3,347,826
12	Extraordinary item	-	-	-	-	-
13	Net profit/(Loss) for the period	261,309	-372,485	-1,609,474	-685,732	-3,347,826
14	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	14,399,361	15,085,116	18,432,942	14,399,361	15,815,613
	Earning Per Share					
(a)	Basic	0.09	-0.12	-0.53	-0.22	-1.10
(b)	Diluted	0.09	-0.12	-0.53	-0.22	-1.10

PART II

Sr. No.	Particular	Quarter Ended			Year Ended	
		31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16
		Audited	Unaudited	Audited	Audited	Audited
A	PARTICULAR OF SHAREHOLDING					
1	Public Shareholdin					
	Number of Shares	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00
	Percentage of Shareholding	35.78%	35.78%	35.78%	35.78%	35.78%
2	Promoters and Promoters Group Shareholding					
a)	Pledge/Encumbered					
	Number of Shares	0	0	0	0	0
	Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	0	0	0	0	0
	Percentage of Shares (as a % of the total share capital of the Company)	0	0	0	0	0
b)	Non - encumbered					
	Number of Shares	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00
	Percentage of Shares (as a % of the total Shareholding of the promoter and promoter Group)	100.00%	100.00%	100.00%	100.00%	100.00%
	Percentage of Shares (as a % of the total Share Capital of the Company)	64.22%	64.22%	64.22%	64.22%	64.22%



Handwritten signature in blue ink.

Statement of Asset and Liabilities			
Particulars		Current year ended	Previous year ended
Date of start of reporting period		1/4/2016	1/4/2015
Date of end of reporting period		31/3/2017	31/3/2016
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Equity and liabilities			
1	Shareholders' funds		
	Share capital	30,545,000	30,545,000
	Reserves and surplus	14,399,361	15,085,116
	Money received against share warrants		
	Total shareholders' funds	44,944,361	45,630,116
2	Share application money pending allotment	-	-
3	Deferred government grants		
4	Minority interest		
5	Non-current liabilities		
	Long-term borrowings	7,500,000	7,500,000
	Deferred tax liabilities (net)		
	Foreign currency monetary item translation difference liability account		
	Other long-term liabilities		
	Long-term provisions	-	-
	Total non-current liabilities	7,500,000	7,500,000
6	Current liabilities		
	Short-term borrowings	-	-
	Trade payables	100,000	-
	Other current liabilities	7,576,501	7,199,359
	Short-term provisions	154,000	139,000
	Total current liabilities	7,830,501	7,338,359
	Total equity and liabilities	60,274,862	60,468,475
Assets			
1	Non-current assets		
(i)	Fixed assets		
	Tangible assets	36,331,961	31,756,399
	Producing properties		
	Intangible assets	-	-
	Preproducing properties		
	Tangible assets capital work-in-progress		
	Intangible assets under development or work-in-progress		
	Total fixed assets	36,331,961	31,756,399
(ii)	Non-current investments	-	1,131,790
(iii)	Goodwill on consolidation		
(v)	Deferred tax assets (net)	117,620	104,915
(vi)	Foreign currency monetary item translation difference asset account	-	-
(vii)	Long-term loans and advances	21,500,000	25,100,000
(viii)	Other non-current assets	-	-
	Total non-current assets	57,949,581	58,093,104
2	Current assets		
	Current investments	-	-
	Inventories	706,763	-
	Trade receivables	-	-
	Cash and bank balances	471,788	96,672
	Short-term loans and advances	-	-
	Other current assets	1,146,730	2,278,699
	Total current assets	2,325,281	2,375,371
	Total assets	60,274,862	60,468,475

Notes :

- The above financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 29, 2017, and the Statutory Auditor have audited the financial results.
- In pursuance of Regulation 47 of SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015, the company has opted for the publication of financial results during this financial year.
- The company Business activity fall within a single business segment, i.e. Floriculture Business, and Accounting Standard 17 titled 'Segment Reporting' is not applicable.
- The Chief Financial Officer have certified that the financial result for the quarter ended & year ended March 31,2017, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statement or figures contained therein misleading.
- Figures of previous quarter/year have been regrouped/rearranged wherever necessary.



By order of the Board

Yogesh Agrawal
Yogesh Agrawal
Managing Director

DIN-01165288

Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063

Place : Delhi
Dated : 29/05/2017



A.K. Khattar & Associates
Chartered Accountants

112-A, Ground Floor, DDA Complex,
Jhandewalan Extn-1, New Delhi-110055
Ph: 011-23676383, 011-43570260

Auditor's Report On Quarterly and Yearly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

Board of Directors of Genomic Valley Biotech Limited

We have audited the quarterly and yearly financial results of **Genomic Valley Biotech Limited** for the quarter and year ended **31st March, 2017**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly and yearly financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly and yearly financial results:


- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit for the quarter ended & net loss for the year ended and other financial information for the quarter and year ended **31st March, 2017**.

DATED: 29.05.2017

PLACE: DELHI

For A K KHATTAR & ASSOCIATES
CHARTERED ACCOUNTANTS




AK KHATTAR
(PROPRIETOR)
M.NO. 084960

GENOMIC VALLEY BIOTECH LTD.

Regd. Off: 4 K.M. Stone, Berri Chhara Road, Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507

CIN: L01122HR1996PLC033029

Tele :- +91-9811341542

Email : genomicvalley@gmail.com

Visit : <http://www.genomicvalley.com>

Declaration of Un-Modified Audit Report pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

We, Yogesh Agrawal, Managing Director and Lalit Shah, Chief Financial Officer of Genomic Valley Biotech Limited having its Registered Office at 4 K.M. Stone, Berri Chhara Road, Village-Kherka Musalman, P.O. Tandaheri, Tehsil- Bahadurgarh, Distt.- Jhajjar, Haryana-124507, hereby declare that A. K. Khattar & Associates, Chartered Accountants (M. No. 084960), Statutory Auditors of the Company, have issued an Auditor Report with Un-Modified opinion on Audited Financial Results of the Company (Standalone) for the quarter and year ended 31st March, 2017.

This declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and Circular no. CIR/ CFD/ CMD/56/2016 dated May, 27, 2016.

For Genomic Valley Biotech Limited



Yogesh Agrawal
Managing Director
DIN No. 01165288

Address: G-74, G-Block,
Pushkar Enclave, Paschim Vihar,
Delhi -110063



Lalit Shah
Chief Financial Officer
PAN No. BCHPS9526B

Address: Flat No. 303, Pacific Tower,
Omaxe City, Rohtak Road,
Bahadurgarh 124507

Date: 29/05/2017

Place: Delhi